What should it take to describe a substance or product as “sperm‐safe”

Show simple item record

dc.contributor.author Mortimer, David
dc.contributor.author Barratt, Christopher L.R.
dc.contributor.author Björndahl, Lars
dc.contributor.author De Jager, Christiaan
dc.contributor.author Jequier, Anne M.
dc.contributor.author Muller, Charles H.
dc.date.accessioned 2013-04-19T08:55:55Z
dc.date.available 2014-01-30T00:20:03Z
dc.date.issued 2013
dc.description.abstract BACKGROUND: Male reproductive potential continues to be adversely affected by many environmental, industrial and pharmaceutical toxins. Pre‐emptive testing for reproductive toxicological (side‐)effects remains limited, or even non‐existent. Many products that come into direct contact with spermatozoa lack adequate testing for the absence of adverse effects, and numerous products that are intended for exposure to spermatozoa have only a general assumption of safety based on the absence of evidence of actual harm. Such assumptions can have unfortunate adverse impacts on at‐risk individuals (e.g. couples who are trying to conceive), illustrating a clear need for appropriate up‐front testing to establish actual “sperm safety”. METHODS: After compiling a list of general areas within the review’s scope relevant literature and other information was obtained from the authors’ personal professional libraries and archives, and supplemented as necessary using PubMed and Google searches. Review by co‐authors identified and eliminated errors of omission or bias. RESULTS: This review provides an overview of the broad range of substances, materials and products that can affect male fertility, especially through sperm fertilizing ability, along with a discussion of practical methods and bioassays for their evaluation. It is concluded that products can only be claimed to be “sperm‐safe” after performing objective, properly designed experimental studies; extrapolation from supposed predicate products or other assumptions cannot be trusted. CONCLUSIONS: We call for adopting the precautionary principle, especially when exposure to a product might affect not only a couple’s fertility potential but also the health of resulting offspring and perhaps future generations. en_US
dc.description.librarian hb2013 en_US
dc.description.uri http://www-humupd.oxfordjournals.org. en_US
dc.identifier.citation Mortimer, D, Barratt, CLR, Björndahl, L, De Jager, C, Jequier, AM & Muller, CH 2013, 'What should it take to describe a substance or product as “sperm‐safe”, Human Reproduction Update, vol.19, supplement 1, pp. i1–i48 en_US
dc.identifier.issn 1355-4786 (print)
dc.identifier.issn 1460-2369 (online)
dc.identifier.other 10.1093/humupd/dmt008
dc.identifier.uri http://hdl.handle.net/2263/21332
dc.language.iso en en_US
dc.publisher Oxford University Press en_US
dc.rights © The Author 2013. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Human Reproduction Update. following peer review. The definitive publisher-authenticated version Human Reproduction Update, Vol.19, Supplement 1 pp. i1–i48, 2013 is available online at : http://www-humupd.oxfordjournals.org en_US
dc.subject Spermatozoa en_US
dc.subject Toxicity en_US
dc.subject Safety en_US
dc.subject Male fertility en_US
dc.subject Pharmacology en_US
dc.title What should it take to describe a substance or product as “sperm‐safe” en_US
dc.type Postprint Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record